These germline alterations could have a crucial role in determining how a tumor responds to EGFR-TKIs; however, few studies (none from Latin America) have examined the clinical usefulness of detecting BIM deletion polymorphisms and its relation with clinical characteristics in EGFR positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.